DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for prolidase deficiency — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleProlidase deficiency maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for prolidase deficiency is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
peptidase D (PEPD) — PEPD is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet mh2drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6QSC · 1.569 Å · ligand MANGANESE ION, 1 HYDROXYL COORDINATED (MH2). Experimental structure, not a prediction.
What the evidence adds up to
Prolidase deficiency is an autosomal recessive disorder caused by a lack of the enzyme that breaks down proline-rich proteins. The condition produces a variable combination of intellectual disability, recurrent infections, splenomegaly, skin lesions, autoimmune problems, and cytopenia. A 2020 review that assembled all molecularly confirmed cases reported to that date found no published review had previously gathered the clinical data, research studies, or therapeutic options for the disease. The review aimed to summarise the state of the art from those descriptions but did not report any controlled treatment data.
A 2011 photographic essay followed one affected individual for 40 years. The documented features included intractable skin ulceration, lymphoedema, recurrent infections, and mild intellectual impairment. The photographs illustrated the natural history of the disease over four decades, but no intervention was tested or described.
A 2021 case report described a male child with prolidase deficiency and focused on the dermatologic features. The authors stated that early diagnosis is important because patients have significant multisystem comorbidities that require multispecialty care. No drug treatment or outcome data were reported in that case.
No abstract reports any clinical trial, any drug tested in patients, or any measurable improvement in survival, skin healing, infection rate, or any other endpoint. What is missing is any funded clinical trial, any validated outcome measure for the skin ulcers or cognitive features, and any patient stratification by residual enzyme activity or genotype that might allow a future trial to detect a treatment effect.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Biology · 2020 · 53 citations · open access
Clinical Genetics of Prolidase Deficiency: An Updated Review
AbstractProlidase is a ubiquitous enzyme that plays a major role in the metabolism of proline-rich proteins. Prolidase deficiency is a rare autosomal recessive inborn metabolic and multisystemic disease, characterized by a protean association of symptoms, namely intellectual disability, recurrent infections, splenomegaly, skin lesions, auto-immune disorders and cytopenia. To our knowledge, no published review has assembled the different clinical data and research studies over prolidase deficiency. The aim of this study is to summarize the actual state of the art from the descriptions of all the patients with a molecular diagnosis of prolidase deficiency reported to date regarding the clinical, biological, histopathological features, therapeutic options and functional studies.
AbstractProlidase deficiency is a rare inherited connective tissue disorder characterised by intractable skin ulceration, lymphoedema, recurrent infections and mild intellectual impairment. We have documented the progress of an affected individual over the past 40 years, illustrated by high quality photographs to demonstrate the natural history of prolidase deficiency.
AbstractProlidase deficiency is an extremely rare, autosomal recessive disorder resulting in defective collagen formation. We report a case of prolidase deficiency in a male child, highlighting the dermatologic features. Early diagnosis is important as these patients encounter significant multisystem comorbidities requiring multispecialty care.
Giornale Italiano di Dermatologia e Venereologia · 2020 · 0 citations
Prolidase deficiency in two dermatological patients in western Sicily
AbstractProlidase deficiency is a rare disorder inherited through an autosomal recessive gene. The hallmark of the disorder are iminodipeptiduria, chronic skin ulcers, recurring infections, mental retardation and characteristic facial appearance, although prolidase deficiency can occur with no clinical manifestation. The primary biological function of the enzyme involves the metabolism of collagen degradation products and the recycling of proline for collagen resynthesis. We describe two patients with prolidase deficiency and review the different clinical manifestations suggesting the pathogenetic mechanism through few hypotheses.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
